08/28/2026
BREAKING NEWS: New Hope in Pancreatic Cancer Treatment 💜
The FDA has approved Rasonque (daraxonrasib), a new targeted therapy for certain adults with metastatic pancreatic adenocarcinoma.
In a clinical trial, median overall survival was 13.2 months with Rasonque compared with 6.7 months with standard chemotherapy.
For a disease with far too few treatment options, this is an important step forward and a powerful reminder of why research and clinical trials matter.
Today, there is progress. Today, there is more hope. 💜